Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks
Open Access
- 1 November 2025
- journal article
- research article
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (1) , 189-198
Abstract
Background The efficacy and safety of once-daily roflumilast foam 0.3%, a potent phosphodiesterase 4 inhibitor, has been demonstrated in patients with seborrheic dermatitis (SD). Objectives To evaluate long-term effects of roflumilast foam 0.3% in patients with SD. Methods A phase II, open-label trial (no. NCT04445987) was conducted in patients (aged ≥ 12 years) with SD who completed a prior roflumilast foam trial or were naïve to roflumilast and vehicle. Patients applied roflumilast foam 0.3% once daily to all affected areas, including the scalp, face, trunk, and intertriginous areas, for 24 or 52 weeks (during the course of the trial, the protocol was amended to extend the duration of treatment from 24 weeks to 52 weeks). The primary endpoints were occurrence of treatment-emergent adverse events (AEs); local tolerability and efficacy (via Investigator Global Assessment [IGA]) were also assessed. Results Overall, 400 patients participated, among whom 62 were enrolled for 52 weeks. AE rates were low, and ≤ 1.1% reported stinging sensation at the application site at each visit. Durable improvement in signs and symptoms of SD was observed at weeks 24 and 52, with 76.0% and 80.4% of patients, respectively, achieving an IGA of clear or almost clear. Conclusions Roflumilast foam 0.3% was well tolerated and improved and/or maintained improvements in signs and symptoms of SD for up to 52 weeks. ClinicalTrials.gov Listing NCT04445987.Keywords
Funding Information
- Arcutis Biotherapeutics Inc.
This publication has 32 references indexed in Scilit:
- Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture ChangesThe Journal of Pharmacology and Experimental Therapeutics, 2016
- The phosphodiesterase 4 inhibitor roflumilast augments the Th17-promoting capability of dendritic cells by enhancing IL-23 production, and impairs their T cell stimulatory activity due to elevated IL-10International Immunopharmacology, 2016
- A putative antipruritic mechanism of the phosphodiesterase‐4 inhibitor E6005 by attenuating capsaicin‐induced depolarization of C‐fibre nervesExperimental Dermatology, 2015
- Seborrheic Dermatitis and Dandruff: A Comprehensive ReviewJournal of Clinical and Investigative Dermatology, 2015
- The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritisInternational Journal of Dermatology, 2014
- Seborrheic dermatitis: Etiology, risk factors, and treatments:Clinics in Dermatology, 2013
- The Impact of Pruritus on Quality of LifeArchives of Dermatology, 2011
- Seborrheic dermatitis.2010
- ScalpdexArchives of Dermatology, 2002
- THE INTERNATIONAL CONFERENCE ON HARMONIZATION GOOD CLINICAL PRACTICE GUIDELINEQuality Assurance, 1999